HUAKANG PHARMACEUTICAL
HUAKANG PHARMACEUTICAL, headquartered in China, is a prominent player in the pharmaceutical industry, specialising in the research, development, and manufacturing of high-quality generic and innovative drugs. Founded in 2001, the company has established a strong presence in major operational regions across Asia and beyond, focusing on therapeutic areas such as oncology, cardiology, and neurology. With a commitment to excellence, HUAKANG PHARMACEUTICAL offers a diverse portfolio of products, including active pharmaceutical ingredients (APIs) and finished dosage forms. Their unique approach to quality assurance and regulatory compliance has positioned them as a trusted partner in the global market. Notable achievements include successful collaborations with international pharmaceutical companies, underscoring their reputation for reliability and innovation in the healthcare sector.
DitchCarbon Score
How does HUAKANG PHARMACEUTICAL's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
HUAKANG PHARMACEUTICAL's score of 7 is lower than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
HUAKANG PHARMACEUTICAL's reported carbon emissions
HUAKANG PHARMACEUTICAL, headquartered in CN, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. The lack of emissions data suggests that HUAKANG PHARMACEUTICAL may not have established formal climate commitments or initiatives aimed at reducing its carbon footprint. This places the company in a broader industry context where many pharmaceutical firms are increasingly focusing on sustainability and emissions reduction, often guided by frameworks such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). As of now, HUAKANG PHARMACEUTICAL does not inherit emissions data from any parent or related organizations, indicating that it operates independently in terms of climate reporting. The company may benefit from developing a structured approach to emissions tracking and reduction to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
HUAKANG PHARMACEUTICAL is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
